Valganciclovir/Valcyte Instructions

1. Indications

Valganciclovir/Valcyte is a deoxynucleoside analogue of cytomegalovirus (CMV) DNA polymerase inhibitor, suitable for:

1.Adult patients

1)Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.

2)Prevention of cytomegalovirus disease in high-risk kidney, heart, and kidney-pancreas transplant patients.

2.Pediatric patients

1)Prevention of cytomegalovirus disease in high-risk kidney and heart transplant patients.

2. Dosage and usage

1.Adult dosage

1)Treatment of cytomegalovirus retinitis

Induction: 900mg(two tablets450mg), twice a day for a total of 21days.

Maintenance: 900 mg(Two tablets450mg), once a day.

2)Heart or kidney-Prevention of cytomegalovirus disease in pancreas transplant patients

After transplantationOnce a day within 10 days900mg(Two tablets450mg),until 100days after transplantation.

3)Prevention of cytomegalovirus disease in kidney transplant patients

After transplantation10 days once a day900mg(two Tablets450mg), until 200days after transplantation.

2.Pediatric Dosage

1) Prevention of cytomegalovirus disease in kidney transplant patients aged 4 months to 16

Dosing is given once daily for 10 days after transplantation and until 200 days after transplantation(Note that creatinine clearance is calculated in children using the modified Schwartz formula)

2) Prevention of cytomegalovirus disease in heart transplant patients aged 1months to16

Administer once daily for 10 days after transplantation and until 100 days after transplantation(Note that creatinine clearance is calculated in children using the modified Schwartz formula) based on dosing algorithm.

Three. Dosage form and strength

Tablets: 450mg.

Oral solution: 50mg per ml.

Four. Contraindications

Allergy to valganciclovir or cyclovir.

Five. Warnings and Precautions

Acute renal failure:Acute renal failure may occur in elderly patients(With or without decreased renal function), patients receiving concomitant nephrotoxic drugs, or patients with insufficient fluid intake. Use with caution in elderly patients or patients taking nephrotoxic drugs. In patients with renal impairment, reduce the dose and monitor renal function.

6. Adverse reactions

Adult patients:The most common adverse reactions and laboratory abnormalities(greater than or equal to 20% in at least one indication span>Patient reports)are diarrhea, pyrexia, fatigue, nausea, tremor, neutropenia, anemia, leukopenia, thrombocytopenia, headache, insomnia, urinary tract infection, and vomiting.

Pediatric patients:The most common adverse reactions and laboratory abnormalities(reported in greater than or equal to 20% of pediatric solid organ transplant recipients) were diarrhea, pyrexia, upper respiratory tract infection, urinary tract infection, vomiting, neutropenia, leukopenia, and headache.

7. drug interactions

1)imipenem-cilastatin:Seizures occurred in patients receiving ganciclovir and imipenem-cilastatin. Concurrent use is not recommended unless the potential benefits outweigh the risks.

2)Cyclosporine or amphotericinB:The risk of nephrotoxicity may be increased when used concomitantly with valganciclovir. Monitor kidney function.

3)Mycophenolate mofetil(MMF):The risk of hematologic and renal toxicity may be increased when combined with valganciclovir. Ganciclovir andMMFtoxicity monitoring.

4)Other drugs associated with myelosuppression or nephrotoxicity:Due to the potential for increased toxicity, concomitant use with valganciclovir should only be considered when the potential benefits are judged to outweigh the risks.

5)Didanosine:Ganciclovir combined with didanosine can increase didanosine levels. Monitor for didanosine toxicity(such as pancreatitis).

6)Probenecid:May increase ganciclovir levels. Monitor for evidence of ganciclovir toxicity.

8. Used by specific groups of people

Breastfeeding:The use ofvalganciclovir for breastfeeding is not recommended.

The retail price of the Turkish version of the original drug in pharmacies0.45g*60tablets2 is more than a thousand. The retail price of original medicine in India is about 0.45g*60 tablets4 around one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.